Semaglutide: A Proven GLP-1 Option Semaglutide, the active ingredient in Wegovy and Ozempic, is a GLP-1 receptor agonist specifically approved by the FDA for chronic weight management
Research on rebound weight gain after discontinuation of GLP-1 drugs shows that many users regain weight within a timeframe similar to their usage period
Antioxidant therapy for infertile couples: a comprehensive review of the current status and consideration of future prospects
DPP-4 Inhibitors DPP-4 inhibitors did not show cardiovascular benefits in meta-analyses by other researchers and ourselves.16,17,55 A previous meta-analysis concluded significant reductions in MACE, but the inclusion of trials with shorter follow-up periods may limit the robustness of the conclusions
In general, though, you can stay on semaglutide long-term to help maintain your weight
They can provide personalized advice based on your specific health needs and medication regimen